Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BROLUCIZUMAB-DBLL: 2,802 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
2,802
Total FAERS Reports
198 (7.1%)
Deaths Reported
170
Hospitalizations
2,802
As Primary/Secondary Suspect
9
Life-Threatening
149
Disabilities
Prescription
Status

FDA Application: 761125 ·

First Report: 20120101 · Latest Report: 20250802

What Are the Most Common BROLUCIZUMAB-DBLL Side Effects?

#1 Most Reported
Vitreous floaters
479 reports (17.1%)
#2 Most Reported
Visual impairment
446 reports (15.9%)
#3 Most Reported
Vision blurred
416 reports (14.8%)

All BROLUCIZUMAB-DBLL Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Vitreous floaters 479 17.1% 4 18
Visual impairment 446 15.9% 1 28
Vision blurred 416 14.9% 2 15
Eye inflammation 387 13.8% 2 10
Visual acuity reduced 365 13.0% 1 19
Retinal vasculitis 323 11.5% 3 22
Uveitis 305 10.9% 1 16
Vitritis 284 10.1% 2 19
Eye pain 234 8.4% 0 18
Vitreous opacities 205 7.3% 1 15
Anterior chamber cell 199 7.1% 2 15
Blindness 191 6.8% 3 20
Keratic precipitates 183 6.5% 1 8
Death 178 6.4% 177 2
Drug ineffective 170 6.1% 0 5
Ocular hyperaemia 158 5.6% 0 13
Iritis 140 5.0% 0 7
Retinal artery occlusion 136 4.9% 1 13
Iridocyclitis 122 4.4% 0 8
Retinal vascular occlusion 112 4.0% 2 10

Who Reports BROLUCIZUMAB-DBLL Side Effects? Age & Gender Data

Gender: 57.3% female, 42.7% male. Average age: 76.6 years. Most reports from: US. View detailed demographics →

Is BROLUCIZUMAB-DBLL Getting Safer? Reports by Year

YearReportsDeathsHosp.
2012 1 0 0
2013 1 0 0
2014 1 0 1
2019 204 0 12
2020 738 27 53
2021 302 24 31
2022 156 14 24
2023 94 4 13
2024 67 3 6
2025 26 0 6

View full timeline →

What Is BROLUCIZUMAB-DBLL Used For?

IndicationReports
Neovascular age-related macular degeneration 1,535
Product used for unknown indication 583
Age-related macular degeneration 445
Choroidal neovascularisation 104
Polypoidal choroidal vasculopathy 64
Diabetic retinal oedema 60
Macular degeneration 51
Retinal vein occlusion 15
Detachment of retinal pigment epithelium 8
Diabetic retinopathy 7

BROLUCIZUMAB-DBLL vs Alternatives: Which Is Safer?

BROLUCIZUMAB-DBLL vs BROMAZEPAM BROLUCIZUMAB-DBLL vs BROMFENAC BROLUCIZUMAB-DBLL vs BROMHEXINE BROLUCIZUMAB-DBLL vs BROMOCRIPTINE BROLUCIZUMAB-DBLL vs BROTIZOLAM BROLUCIZUMAB-DBLL vs BUCILLAMINE BROLUCIZUMAB-DBLL vs BUDESONIDE BROLUCIZUMAB-DBLL vs BUDESONIDE\FORMOTEROL BROLUCIZUMAB-DBLL vs BUDESONIDE\FORMOTEROL\GLYCOPYRROLATE BROLUCIZUMAB-DBLL vs BUDESONIDE\FORMOTEROL\GLYCOPYRRONIUM

Official FDA Label for BROLUCIZUMAB-DBLL

Official prescribing information from the FDA-approved drug label.